IKT

Business Context and Reporting Period

Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2025
Business Overview: Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a novel oral prodrug of imatinib, for the treatment of Pulmonary Arterial Hypertension (PAH). The company discontinued its Parkinson's disease program (risvodetinib) and outlicensed it to ABLi Therapeutics in May 2025. The company is preparing to initiate the IMPROVE-PAH Phase 2b clinical trial in the second half of 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Acquisition of CorHepta: In February 2025, the company acquired CorHepta Pharmaceuticals, Inc. in an asset acquisition. This resulted in a one-time non-cash write-off of $7.36 million for in-process research and development (IPR&D) and the recognition of a $2.91 million contingent consideration liability.
• Expense Increases: Total operating expenses increased significantly due to the CorHepta acquisition costs, increased stock-based compensation ($6.25 million vs. $0.08 million), and the ramp-up of PAH program expenses. R&D expenses rose 170.9% and SG&A expenses rose 178.8% compared to the prior six-month period.
• Discontinued Program: Expenses related to the discontinued Parkinson's disease program decreased by approximately $4.8 million compared to the prior period.
• Financing Activity: The company raised approximately $99.6 million in net proceeds from a private placement in October 2024. In the current period, financing cash flows were minimal ($31,771) compared to $3.6 million in the prior year, as the major capital raise occurred in the previous fiscal year.
• Investing Activities: Net cash provided by investing activities was $30.9 million, primarily driven by $31.4 million in maturities of marketable securities, contrasting with a net use of cash in the prior period.

Guidance, Outlook, and Risks

• Clinical Outlook: The company expects to initiate the IMPROVE-PAH Phase 2b trial (approx. 150 patients) in the second half of 2025. Subsequent events indicate the company has entered into agreements totaling approximately $28.8 million for clinical trial supply and research organization services for this study.
• Liquidity: Management estimates that cash, cash equivalents, and marketable securities of approximately $87.7 million as of June 30, 2025, are sufficient to fund operations for at least the next twelve months.
• Capital Needs: The company anticipates needing substantial additional funding for future operations and clinical trials. It may seek additional equity or debt financing, which could result in dilution.
• Risks:
  • Regulatory: Reliance on the 505(b)(2) pathway for FDA approval; potential changes in healthcare legislation (e.g., Inflation Reduction Act, new tax laws like the "One Big Beautiful Bill").
  • Supply Chain: Dependence on third-party manufacturers located in China, exposing the company to trade tariffs and geopolitical risks.
  • Development: Risks associated with clinical trial enrollment, safety, and efficacy of IKT-001.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $87.7 million liquidity position against the newly disclosed $28.8 million in clinical trial commitments and ongoing operational burn rates.
• Acquisition Accounting: Review the valuation and vesting conditions of the $2.91 million contingent consideration liability from the CorHepta acquisition.
• Stock-Based Compensation: Assess the impact of the $6.25 million stock-based compensation expense on future cash flow and dilution, noting the significant increase from the prior year.
• ATM Facility: Confirm the status of the new $200 million Open Market Sale Agreement with Jefferies LLC entered into on June 20, 2025, and any potential sales under this facility.
• Patent Expiry: Verify the timeline for patent protection (currently until 2033) and the status of upcoming filings to extend protection to 2045.